A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 117 participants.
Also called NCT01529528
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 117 participants
- Sponsor
- Registry
-
NCT01529528
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01529528. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
- Acronym
- CWP-DIANA-301
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Anagliptin
- Intervention (Drug)
- Anagliptin
- Intervention (Drug)
- Placebo of Anagliptin
- Lead sponsor
- JW Pharmaceutical
Record details
- Record id
cardio:ct-nct01529528- Content hash
36655502086bdc77def1c9460ce49eed005934f4aa8d137e709ceca147d6c29d